Nationwide Recall of Chlorthalidone Blood‑Pressure Pills: What Pakistani Patients Need to Know

Nationwide Recall of Chlorthalidone Blood‑Pressure Pills: What Pakistani Patients Need to Know

High blood pressure (hypertension) is a leading risk factor for heart disease and stroke in Pakistan. A sudden, large‑scale recall of a common diuretic – chlorothalidone 25 mg tablets – has raised concerns for anyone who relies on generic imports. Below we break down the scope of the recall, why the pills failed quality testing, what steps patients should take, and how the situation may affect pharmacies and consumers across Pakistan.

Scope of the Recall

• Manufacturer: Inventia Healthcare Limited, an India‑based generic drug maker.
• Recall type: FDA Class II (moderate health risk; unlikely to cause serious harm but requires prompt action).
• Total bottles affected: 25,027 (13,567 recalled on 3 September 2026, 11,460 recalled on 5 June 2026).
• Product: Chlorthalidone tablets, USP, 25 mg, 100‑count bottles.
• Batch numbers:
  • RISA24001 (June recall, 100‑count bottles)
  • RISB24002 (June recall, 1,000‑count bottles)
  • RISA24002 (September recall, 100‑count bottles)
• Expiration date: April 2027 for all recalled batches.
• Physical description: Light‑yellow, round, flat tablets stamped with “103” on one side; the other side is blank.

The recall covers both the United States market and any downstream shipments that may have reached South Asia, including Pakistan, through parallel import channels.

Why the Pills Failed: Dissolution Testing

The FDA’s enforcement notice cites “Failed Dissolution Specifications.” Dissolution testing measures how quickly a tablet releases its active ingredient once ingested. If a tablet dissolves too slowly or not at all, the patient may receive a sub‑therapeutic dose, leaving blood pressure uncontrolled. The key points:

• No contamination: The failure is not due to a foreign substance (e.g., aluminum) but to the tablet’s physical performance.
• Potential clinical impact: Inconsistent dosing can lead to spikes in blood pressure, increasing the risk of cardiovascular events.
• No reported injuries: As of the latest reports, no adverse events have been directly linked to the defective batches.

How to Identify Affected Bottles

Pakistani patients who obtain chlorthalidone from local pharmacies, online stores, or personal imports should check the following details on the bottle label:

1. National Drug Code (NDC): 64980-599-01.
2. Lot / Batch number: One of the three numbers listed above.
3. Expiration date: Any bottle expiring April 2027.
4. Physical appearance: Light‑yellow tablets with a “103” imprint.

If any of these identifiers match the recall information, the medication should be set aside and not consumed.

Immediate Steps for Patients

1. Do not panic, but do not take the pills. Stop using the medication until you have confirmed its status.
2. Locate the bottle and write down the NDC, lot number, expiration date, and pharmacy where it was dispensed.
3. Contact your pharmacist within 24 hours. Provide the details you recorded; the pharmacist can verify whether the batch is part of the recall.
4. Call your prescriber (physician or cardiologist). Discuss alternative antihypertensive options such as lisinopril, amlodipine, or a different diuretic.
5. Report the issue to the Drug Regulatory Authority of Pakistan (DRAP) via their online portal or toll‑free line. This helps regulators track imported recalls.
6. Dispose of the medication safely if confirmed as recalled – use a pharmacy‑backed take‑back program or follow DRAP’s disposal guidelines.

Guidance for Pharmacies and Healthcare Providers

• Inventory audit: Conduct an immediate stock‑take of all chlorthalidone 25 mg tablets. Flag any bottles with the recalled lot numbers.
• Patient outreach: Use prescription records to identify patients who received the affected batches. Proactively call them with the information above.
• Alternative sourcing: Secure a reliable supply of an equivalent antihypertensive from a manufacturer with a clean FDA or DRAP record. Document the switch in the patient’s medication history.
• Documentation: Record the recall notice in the pharmacy’s adverse‑event log. This may be required for future audits.
• Staff training: Brief all dispensing staff on how to read NDC and lot numbers, and on the importance of verifying recall status before dispensing.

Potential Impact on the Pakistani Market

1. Supply chain disruption: Many Pakistani pharmacies rely on low‑cost generic imports from India and other Asian manufacturers. The recall could create a short‑term shortage of chlorthalidone, prompting price spikes.
2. Regulatory scrutiny: DRAP may increase inspections of imported antihypertensives, especially those from the same manufacturer, to ensure compliance with local Good Manufacturing Practices (GMP).
3. Patient confidence: Repeated recalls can erode trust in generic medicines. Clear communication from healthcare providers is essential to maintain adherence to treatment.
4. Opportunity for alternatives: The situation may accelerate the adoption of other first‑line agents recommended by the Pakistan Hypertension League, such as ACE inhibitors or calcium‑channel blockers.

What Regulators Are Doing

• FDA (USA): Classified the recall as Class II and issued public notices through the FDA Enforcement Report. The agency continues to monitor the manufacturer’s future batches.
• DRAP (Pakistan): Has a formal mechanism for reporting foreign recalls. The agency is expected to issue an advisory to all licensed importers and distributors, urging them to quarantine any stock that matches the recalled specifications.
• World Health Organization (WHO): Lists Inventia Healthcare in its pre‑qualification database; a recall may trigger a review of the company’s status for future procurement.

Alternatives and Managing Blood Pressure During the Recall

Patients should not switch medications without a doctor’s advice. A temporary change to a different class can keep blood pressure under control while the supply issue is resolved.

Practical Checklist for Patients

• Verify NDC, lot number, and expiry date on the bottle.
• Call the pharmacy that dispensed the medication.
• Speak to your prescribing doctor about alternatives.
• Report the recall to DRAP.
• Dispose of the recalled tablets safely.
• Keep a written record of all communications for future reference.

Conclusion

The large‑scale recall of Inventia Healthcare’s 25 mg chlorthalidone tablets underscores the importance of rigorous quality testing for generic medicines. While the defect relates to dissolution – not contamination – the potential for under‑dosing makes swift action essential. Pakistani patients who may have imported or purchased these tablets should verify their stock, contact healthcare professionals, and follow DRAP’s guidance. Pharmacies must audit inventory and communicate proactively to avoid treatment gaps. By staying informed and acting promptly, patients can maintain blood‑pressure control and protect their cardiovascular health despite the recall.

Stay tuned to KM Afaq for updates on drug safety, regulatory actions, and practical health advice for Pakistan.